|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 10, Num. 3, 2005, pp. 223-230
|
Middle East Fertility Society Journal, Vol. 10, No. 3, 2005, pp. 223-230
Prevalence and predictors of risk for type 2 diabetes
mellitus and impaired glucose tolerance in polycystic ovary syndrome
Maida
Yousif Shamdeen, M.R.C.O.G.*, Maha
Amer Saber, MB.Ch.B.
Al-batool
Maternity Teaching Hospital, infertility center, Iraq
*Assist Professor, Head of
Obstet & Gynecol Department, MosulMedicalCollege
Registrar in Al-batool
Maternity Teaching Hospital
Correspondence: Dr. Maid Shamdeen, MRCOG,
E-mail: maida_yousif@yahoo.com
Received on January 12, 2005;
revised and accepted on June 21, 2005
Code Number: mf05039
ABSTRACT
Objective: To determine the prevalence of glucose
intolerance and parameters associated with risk in polycystic ovary syndrome
(PCOS) patients.
Design: case control study
Setting: Al-batool Maternity Teaching Hospital,
infertility center.
Materials and methods: From October 2001 to October
2002, one hundred women with, aged 18-44years met conventional clinical criteria
for
PCOS, and had ovarian sources of androgen excess, were compared with 60 control
women of similar weight and age. Anthropometric measurement the weight, height,
and waist: hip measurements and body mass index (BMI) were assessed; two groups
were identified, over weight BMI 25 kg/m² and obese as BMI 30kg/m². Fasting
serum glucose (FSG), Oral glucose tolerance (OGT) and serum fasting
testosterone were done. Patients were divided into three groups: (non
diabetics, diabetics and impaired glucose tolerance).
Results: the prevalence of glucose intolerance
was significantly higher in PCOS than the controlled group, the risk of glucose
intolerance and diabetes was increased with the age, obesity, and the first
degree relatives.
Conclusions: PCOS women are at significantly
increased risk for impaired glucose tolerance and type 2 diabetes mellitus at
all weight and at young age.
Key ward: PCOS, Insulin resistance, type 2
diabetes mellitus, impaired glucose tolerance.
Women with polycystic ovary
syndrome (PCOS) are insulin resistant, and at high risk for glucose
intolerance. Most physicians would agree that PCOS could be diagnosed clinically
in a woman, who has hirsutism, irregular menstrual cycles, obesity, and a
classic ovarian morphology, by echography. After considerable debate at 1990
National Institutes of Health Conference on PCOS, two minimal criteria were
proposed; Menstrual irregularity, and evidence of hyperandrogenism, whether
clinical or biochemical (1-5).
The
association between disorders of carbohydrate metabolism and hyperandrogenism
was first described in 1921 by Achard and Thiers. PCOS is an exceptionally
common disorder of premenopausal women with 5-10% prevalence, 20% of
self-selected normal women had polycystic ovary morphology on ovarian
ultrasound (1-2), and found in up to 75% of women with secondary amenorrhea
(1-3, 6, 7). Since the report by Burghen et al. in 1980 which showed that PCOS
was associated with hyperinsulinemia, the syndrome has major metabolic as well
as reproductive morbidities (1, 8-12). Most
anovulatory patients (approximately 80%) present with serum FSH and
estradiol levels within the normal range (World Health Organization class II)
(13). The skin lesion, acanthosis nigricans, was reported in women with
hyperandrogenism and diabetes mellitus by Kierland et al in 1947(14-18), and
Kahn and colleagues in 1976 when described a distinct disorder affecting
adolescent girls, which they designated the type A syndrome, this group
identified a second distinct extreme insulin resistance syndrome in
postmenopausal women with acanthosis nigricans and features of autoimmune
disease, termed the type B syndrome and determined that it was caused by
endogenous anti-insulin receptor antibodies (17-19). Brown and Winkelmann
noted in 1968 that it was insulin-resistant diabetes mellitus, and genetic
basis was suggested for that (15-18). Burghen and colleagues reported that
women with PCOS, had basal and glucose-stimulated hyperinsulinemia compared
with weight-matched control women, suggesting the presence of insulin
resistance (20-22). In the mid-1980s several groups noted that these women had
hyperinsulinemia basally and during an oral glucose tolerance test, compared
with
appropriately age- and weight-matched control women (22-23).
Obesity is common, and
most investigators find at least one half of women with PCOS are obese, which
is upper body obesity, with waist-to-hip ratio of greater than 0.85(22-25).
Obesity leads to an increased insulin resistance and a rise in insulin
circulating levels, which leads to an increased ovarian secretion of androgens
and decreased sex hormone binding globulin (26, 27).
Defects in insulin
action in muscle leads to reduced glucose disposal, and enhance the
steroidogenic effects on theca cells and suppress sex hormone - binding
globulin production by hepatocytes, leading to a hyperandrogenemic state
(29-33).
MATERIALS AND METHODS
Over a
period of one year starting from October 2001 to the end of October 2002, one
hundred PCOS women, aged 18-44 yr, attending MosulInfertilityCenter in Al-Batool Maternity Teaching Hospital were
included in this study. All women were in good health, for at least one month
before study, and were not taking any
medication known to affect sex hormone or carbohydrate metabolism. The
diagnosis of PCOS was made by the presence of chronic anovulation in
association with elevated circulating androgen levels (1-2). Non-classical
adrenal 21-hydroxylase deficiency, Hyper-prolactinemia and androgen-secreting
tumors were excluded by appropriate tests before the diagnosis of PCOS was
made. No PCOS patient had diagnosed diabetes mellitus.
The
control group consists of sixty healthy women had regular menstrual cycle every
27-32 days and were not hirsute. To control for conditions altering insulin
action, controlled women did not engaged in regular aerobic exercise, nor did
they have a history of hypertension, a personal history of diabetes, or a
first-degree relative with diabetes.
Anthropometric measurements
Weight and height were recorded with the
subjects wearing light clothing and without shoes. Accurate balance scales were
used and weight was recorded to the nearest 0.1 kg. Height was recorded to the
nearest centimeter rounding up if midway, using measuring rod. The same person
who recorded the height and weight in the same room recorded the waist and hip
measurement, one layer of light clothing over underwear was acceptable. The
observer kneeled or sat at an appropriate height in front of the subject, who
breathed quietly and normally. Dresser makers measuring tape was used, taking
care that it was applied horizontally. Waist girth was measured at the mid
point between the iliac crest and the lower margin of the ribs. An approximate
indicator of this level was ascertained by asking the subject to bend sideways.
Hip girth was recorded as the maximum circumference around the buttock
posteriorly and indicated anteriorly by the symphysis pubis. The obesity was
defined by body mass index BMI calculation as; (weight/height) ² (kg/m) ².
Overweight was defined as a BMI of >25
and obesity as BMI of >30.
Biochemical assessments
Blood samples were taken on
the second visit. An oral glucose tolerance test was performed between 0800-1000h
after an overnight fast of 10-14 h. All subjects were administered a 75g oral
glucose challenge.
Table 1. Clinical and biochemical characteristics.
Variable
|
PCOS women (no. =100)
|
Control women (no. =60)
|
|
|
|
Waist/ hip ratios
|
0.85±0.06(0.70-1.0)
|
0.77±0.07(0.6-0.9)
|
T (nmol/L)
|
2.8±1.3(0.9-1.0)
|
0.9±0.5(0.5-3.2)
|
Fasting glucose (mg/dL)
|
92±18(52-162)
|
85±6(57-115)
|
BMI (kg/m2 )
|
30±6(18-45)
|
26±9(17-42)
|
Age (years)
|
29±6(18-44)
|
28±5(18-44)
|
2-h glucose (mg/dL)
|
130±30(70-208)
|
110±28(60-180)
|
Blood was obtained for glucose determinations at
0 and 2 h. An additional blood sample was obtained at 0 h for testosterone (T).
Plasma glucose (PG) levels were determined by the glucose oxidase method using
automated analyzer. Levels of T were determined by VIDAS analyzer; using the
ELFA technique (Enzyme linked Fluorescent Assay). Glucose tolerance was
assessed by 1985 WHO criteria.
Non-diabetics Group;
this group included subjects with FPG <110 mg/dl (6.1 mmol/L) or 2hPG <
140 mg/dl (<7.8 mmol/L).
Diabetics (DM) Group;
This group included subjects with FPG±140
mg /dl (>7.8 mmol/L) or 2hPG >200 mg/dl (±³11.1 mmol/L) following OGTT. Impaired Glucose Tolerance
(IGT) Group: This group included subjects who had 2hPG values ranged from
140-199 mg/dl (7.8-11.06 mmol/L) following OGTT.
The PCOS women were
studied for diabetes diagnostic categories based on postchallenge glucose
levels, using WHO criteria compared to those determined according to the 1997
ADA (American Diet Association) criteria based on fasting glucose values,
normal fasting glucose, <110 mg/dL (< 6.1 mmol/L); impaired fasting
glucose 110-125 mg/dL (6.1-6.9 mmol/L); diabetes ±126 mg/dL (7.0 mmol/L). A multiple regression analysis was
preformed to determine which variables predicted postchallenge glucose values.
To control for the potential confounding effects of a family history of
diabetes, we included only control and PCOS women without a first degree
relative with diabetes in this analysis. The candidate predictive variables
were status (PCOS vs. control), age; body mass index (BMI), waist/hip ratio,
and fasting glucose values. Androgen values were not considered as candidate
predictive variables, because they were used to make the diagnosis of PCOS. The
criterion for a predictive variable to remain in the model was P±0.15. All analyses were performed using
the SPSS (statistical package for social sciences).
Table 2. Prevalence of glucose intolerance by BMI
in PCOS, and in control group
BMI (kg/m2
|
PCO
|
NGT
|
IGT
|
DM
|
Control
|
NGT
|
IGT
|
DM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BMI
|
total
|
%
|
No.
|
%
|
No.
|
%
|
No.
|
Total
|
%
|
No.
|
%
|
No.
|
%
|
No.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15-19
|
4
|
100
|
4
|
0
|
0
|
0
|
0
|
4
|
100
|
4
|
0
|
0
|
0
|
0
|
20-24
|
17
|
88
|
15
|
12
|
2
|
0
|
0
|
18
|
94
|
17
|
6
|
1
|
0
|
0
|
25-29
|
23
|
65
|
15
|
31
|
7
|
4
|
1
|
26
|
96
|
25
|
4
|
1
|
0
|
0
|
30-34
|
28
|
50
|
14
|
43
|
12
|
7
|
2
|
8
|
87
|
7
|
13
|
1
|
0
|
0
|
35-39
|
22
|
64
|
14
|
27
|
6
|
9
|
2
|
3
|
67
|
2
|
33
|
1
|
0
|
0
|
40-44
|
5
|
60
|
3
|
20
|
1
|
20
|
1
|
1
|
0
|
0
|
100
|
1
|
0
|
0
|
45-49
|
1
|
0
|
0
|
0
|
0
|
100
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
total
|
100
|
65
|
65
|
28
|
28
|
7
|
7
|
60
|
92
|
55
|
8
|
5
|
0
|
0
|
NGT, normal
glucose tolerance: IGT, impaired glucose tolerance.
Table 3. Prevalence of glucose intolerance by age
in PCOS women, and in control group
|
PCO |
NGT |
IGT |
DM |
Control |
NGT |
IGT |
DM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AGE |
Total |
% |
No. |
% |
No. |
% |
No. |
Total |
% |
No. |
% |
No. |
% |
No. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15-19 |
5 |
100 |
5 |
0 |
0 |
0 |
0 |
9 |
100 |
9 |
0 |
0 |
0 |
0 |
20-24 |
17 |
88 |
15 |
12 |
2 |
0 |
0 |
10 |
100 |
10 |
0 |
0 |
0 |
0 |
25-29 |
29 |
72 |
21 |
24 |
7 |
4 |
1 |
16 |
94 |
15 |
6 |
1 |
0 |
0 |
30-39 |
27 |
37 |
10 |
55 |
15 |
8 |
2 |
16 |
87 |
14 |
13 |
2 |
0 |
0 |
35-39 |
16 |
62 |
10 |
19 |
3 |
19 |
3 |
5 |
80 |
4 |
20 |
1 |
0 |
0 |
40-44 |
6 |
66 |
4 |
17 |
1 |
17 |
1 |
4 |
75 |
3 |
25 |
1 |
0 |
0 |
Total |
100 |
65 |
65 |
28 |
28 |
7 |
7 |
60 |
92 |
55 |
8 |
5 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RESULTS
Clinical and biochemical
characteristics of the subjects are summarized in Table 1. Their age ranged
between 18-44 years with a mean of 29.5 years.
Prevalence of glucose
intolerance by BMI (Table 2): In PCOS, and in control group, this showed that;
In PCOS 21% of women were none obese (BMI<25 kg/m ²), 23% were overweight
(BMI>25 kg/m²), and 56% were obese (BM> 30 kg/ m ²). Overall 35% of the
PCOS women had either IGT (28%) or diabetes (7%) by WHO criteria. The non-obese
and overweight PCOS women, 9% had IGT, and 1% had diabetes. In control group
eight percent of the women had IGT, and none had diabetes. Although IGT and
diabetes were detected in non-obese and/or young PCOS women, the prevalence of
both significantly increased with BMI (by Pearson correlation test, P
<0.0001; Table 2) and with age (by Pearson correlation test, P 0.001)
The prevalence of
glucose intolerance studied in PCOS women without a first degree relative with
diabetes (n = 68) compared to that in control women (n = 60), to adjust for
confounding effects of family history of diabetes. These PCOS women were
significantly more obese than control women (30 ± 4 vs. 26 ±9 kg/m2)
respectively, with P value of 0.001, with no significant difference in age (29±
6 vs. 28 ± 5 kg/m2) respectively. They had a significantly higher prevalence of
glucose intolerance (23.6% IGT; 4.4% diabetes) compared to control women (8%
IGT; 0% diabetes; x2=8; P= 0.005; OR = 4; 95% CI =1.5-10.5).
Regarding the impact of
family history of diabetes; the prevalence of glucose intolerance in PCOS women
were compared, and found that it was significantly higher in PCOS women with a
first degree relative with diabetes (50%) vs. 30% no first degree relative with
diabetes; X2= 4.65; P <0.03; OR = 2.57; 95 % CI = 1.09-6).
Comparison of diabetes diagnostic
criteria
The majority of PCOS
women with glucose intolerance had normal fasting glucose levels by ADA criteria. Using the ADA criteria, 4% of PCOS
women would be classified as having diabetes; where-as 7% would be classified
as having diabetes by WHO criteria, a difference of 3%. Thus, 3 of 7 (43%) PCOS
women with diabetes diagnosed by WHO criteria would have been missed using ADA criteria. No PCOS women
considered diabetes by fasting glucose values ,and did not have it by
postchallenge glucose. According to the ADA criteria, 9% of PCOS women had impaired fasting
glucose, whereas 28% had IGT by postchallenge glucose values.
DISCUSSION
Women's
health is about the prevention, screening, diagnoses, and treatment of disorder
that are unique to women. PCOS is extremely prevalent and probably constitutes
the most frequently encountered endocrinopathy in women of reproductive age.
Having the disorder may significantly impact the quality of life of women during
the reproductive years, and it contributes to morbidity and mortality by the
time
of menopause. PCOS women had
a later menopause, and they had experienced a higher hysterectomy rate. Most
importantly, there was a high prevalence of diabetes (16%) and hypertension (40%)
(33, 34).
Table 4. Prevalence of glucose intolerance by W/H
ratio in PCOS women and control group (Without family history of DM)
W/H ratio
|
PCOS
|
NGT
|
IGT
|
DM
|
Control
|
NGT
|
IGT
|
DM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
%
|
No.
|
%
|
No.
|
%
|
No.
|
Total
|
%
|
No.
|
%
|
No.
|
%
|
No.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<0.85
|
25
|
76
|
19
|
24
|
6
|
0
|
0
|
37
|
95
|
35
|
5
|
2
|
0
|
0
|
0.85-0.89
|
18
|
78
|
14
|
22
|
4
|
0
|
0
|
18
|
94
|
17
|
6
|
1
|
0
|
0
|
0.90-0.94
|
16
|
69
|
11
|
25
|
4
|
6
|
1
|
4
|
75
|
3
|
25
|
1
|
0
|
0
|
0.95-0.99
|
8
|
63
|
5
|
25
|
2
|
12
|
1
|
1
|
0
|
0
|
100
|
1
|
0
|
0
|
1.0-1.04
|
1
|
0
|
0
|
0
|
0
|
100
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
total
|
68
|
72
|
49
|
24
|
16
|
4
|
3
|
60
|
92
|
55
|
8
|
5
|
0
|
0
|
This is the
first controlled study of glucose tolerance in PCOS in Mosul city in Iraq, and
we document that these women are at significantly increased risk for IGT and
type 2 diabetes
mellitus compared to concurrently studied age, weight, comparable
reproductively normal women. The prevalence rates of glucose intolerance in
PCOS was 28% IGT, and 7% undiagnosed diabetes, and are substantially higher
than those found in a across- sectional population- based study done in Mosul
city of adult of similar age (3% IGT; 2% undiagnosed diabetes)(35). Dahlgren
et al. noted that in a retrospective, cohort study 15% of women with PCOS had
been
diagnosed with diabetes mellitus compared to 2.3% of controls, after a
follow-up period of 22-31 years (1992)(34). More recently, Legro and colleagues
reported in women with PCOS, with an average age of 29 years, that 7.5% had
type 2 DM and 31% had glucose intolerance (Legro et al 1999)(36). A preliminary
report by Ehrmann and colleagues (37) found similar prevalence rates in an
ethnically mixed PCOS population from the Chicago area (35% of 122 young women
with PCOS had IGT and 10% had NIDDM). Insulin resistance is an important defect
in the
pathogenesis of noninsulin-dependent diabetes mellitus (NIDDM) (1-3, 12, 38).
In a recent study (18) on female subjects from the Mediterranean region, 15.7
and
2.5% displayed impaired glucose tolerance and type 2 diabetes, respectively.
These subjects were included in a single group of overweight or obese subjects
presenting with glucose intolerance (GI) states. PCOS women with normal glucose
tolerance (81.8%) were subdivided into two groups: those who were overweight
or obese and those of normal weight, they found that 2.5% of PCOS women had
type 2
diabetes and 15.7% had IGT. This prevalence rate was significantly higher than
that described in the general population of similar age, but somewhat lower
than that reported in previous studies performed in the U.S. and Asia Although
all PCOS women with GI investigated in this study were obese, it is noteworthy
that nearly 80% of obese PCOS subjects had NGT.
Despite the fact that
hyperinsulinemia, reflecting some degree of peripheral insulin resistance, was
well recognized in PCOS by the mid-1980s, glucose tolerance was not
systematically investigated until Dunaif study in 1987(40), he found that obese
PCOS women had significantly increased glucose levels during an oral glucose
tolerance test compared with age- and weight-matched ovulatory hyperandrogenic
and control women. The effects of insulin on glucose metabolism are usually
examined in studies of insulin resistance (41). This can be studied
quantitatively in humans with the euglycemic glucose clamp technique: a desired
dose of insulin is administered and euglycemic is maintained by a simultaneous
variable glucose infusion (41, 42). At steady state, the amount of glucose that
is infused equals the amount of glucose taken up by the peripheral tissues and
can be used as a measure of peripheral sensitivity to insulin, known as
insulin-mediated glucose disposal. Making a diagnosis of insulin resistance in
an individual is problematic; First, there is a wide range of insulin
sensitivities in normal individuals as 25% of normal subjects have insulin
action values that overlap with those from insulin-resistant individuals,
Second, clinically available measures of insulin action, such as fasting or
glucose-stimulated insulin, do not correlate well with more detailed
measurements of insulin sensitivity in research settings. In view of these constraints,
it is prudent to consider all PCOS women at risk for insulin resistance and
they should have fasting and 2-h post-75g glucose load glucose levels as a
screen for glucose intolerance (43-45).
The age in women studied
ranged from 18-44 years with a mean age of 29 years. Although IGT and diabetes
were detected in young women, the prevalence of both were significantly
increased with age (p<0.001) Table (3).
In the current study,
the non obese PCOS women also have glucose intolerance (9% IGT, 1% diabetes),
but the prevalence rates of glucose intolerance was significantly increased
with BMI (P<0.0001), and an increased W/H ratio was significantly affecting
the rate of IGT (Table 4).
Euglycemic
glucose clamp studies have demonstrated significant and substantial decreases
in insulin-mediated glucose disposal in PCOS (41). This decrease (35-40%) is
of a similar magnitude to that seen in NIDDM. Obesity (fat mass per se), body
fat
location (upper vs. lower body, e.g., waist to hip girth ratio), and muscle
mass all have important independent effects on insulin sensitivity. Since
muscle is the major site of insulin-mediated glucose use, and androgens can
increase muscle mass, potential androgen-mediated changes in lean body
(primarily muscle) mass must also be controlled for in PCOS (41, 48-50). These
detects are much more pronounced in PCOS women who have a first-degree relative
with NIDDM, suggesting that such women may be at particularly high risk to
develop glucose intolerance. Consistent with this hypothesis, we showed that
a
first degree relative with diabetes was associated with an increased risk of
glucose intolerance in PCOS women figure (7). However, the prevalence of
glucose intolerance in PCOS, even in those women without a first degree
relative with diabetes, was still significantly higher than that in control
women Figure 2. However, to our knowledge, no studies have been performed on
subjects from the Mediterranean region before this. Studies in American and
Asian subjects have shown that women with PCOS compared with the general
population have an increased risk for impaired glucose tolerance (IGT) and type
2 diabetes, with a tendency toward early development of glucose intolerance
(GI) states. The strong connection between PCOS and GI states is further
emphasized by the high prevalence of polycystic ovarian morphology found on
ultrasound scans in premenopausal women with type 2 diabetes and those with
previous gestational diabetes (12).
CONCLUSIONS
PCOS women have
significantly increased prevalence rates of IGT and undiagnosed diabetes.
Although obesity and age substantially increase the risk, IGT and diabetes can
occur in young, non-obese PCO women.
Fasting glucose levels
are poor predictors of diabetes in PCOS women. It is advisable to perform an OGTT
at the time of diagnosis of PCOS, and periodically thereafter. Women, who are
diagnosed with polycystic ovarian disease and subsequently get pregnant, should
have routine glucose testing performed in pregnancy, perhaps more than once.
Women who have gestational diabetes in pregnancy should be tested after
pregnancy for polycystic ovaries.
REFERENCES
-
Zawadzki, JK, and Dunaif, A. Diagnostic criteria for
polycystic ovary syndrome: Toward a rational approach. In: polycystic ovary
syndrome, Current Issues in Endocrinology and Metabolism, 1992; 4: chap. 32.
P
377 Blackwell Scientific Publications, Boston
-
Franks S. Polycystic ovary syndrome. N Engl J Med
1995;333:853-61
-
Polson DW, Wadsworth J, Adams J, Franks S. Polycystic
ovaries - a common finding in normal women. Lancet 1988; 1:870-2
-
Corbould A., Kim Y.-B., Youngren J. F., Pender C., Kahn
B. B., Lee A., and Dunaif A. Insulin resistance in the skeletal muscle
of women with PCOS involves intrinsic and acquired defects in insulin signaling.
Am J
Physiol Endocrinol Metab 2005; 288(5): E1047 - E1054.
- Bloomgarden Z. T. Definitions
of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin
Resistance Syndrome. Diabetes
Care 2004; 27(3): 824 - 30.
- Pettersson F, Fries H.
Nillius SJ. Epidemiology of secondary amenorrhea. Am J Obstet Gynecol 1973;117:80-6.
- Hull MGR. Epidemiology
of infertility and polycystic ovarian disease: endocrinological and demographic
studies. Gynecol Endocrinol
1987;1:235-45
- BurghenGA,
Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism
in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113-6
- Dunaif A, Hoffman AR. Insulin
resistance and hyperandrogenism: clinical syndromes and possible mechanisms.
Biorhythms and
Stress in the Physiopathology of Reproduction 1988: p 293-317. Hemisphere
Publishing Co, Washington, DC,
- Barbieri
RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans
syndrome: a common endocrinopathy with distinct pathophysiologic features.
Am J Obstet Gynecol 1983; 147:90
- Poretsky
L, Kalin MF. The gonadotropin function of insulin. Endocr Rev 1987; 8:132-41
- Heather
R. Peppard, Jennifer Marfori, Maria J. Iuorno, and John E. Nestler. Prevalence
of Polycystic Ovary Syndrome among Premenopausal Women with Type 2 Diabetes.
Diabetes Care 24 2001;1050-2
- Laven,
Joop SE, Imani, Babak , Eijkemans, Marinus J. C., Fauser, Bart C. J.M.
New Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory
Infertility. Obstetrical & Gynecological Survey.2002; 57(11):755-67.
- Kierland
RR, Lakatos I, Szijarto L. Acanthosis nigricans: An analysis of data in
twenty-two cases and a study of its frequency in necropsy material. J Invest
Dermatol 1947:9:299-305
- Brown
J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine 1968
47:33-51
- Barnes
ND, Palumbo PJ, Hayles AM, Folgar H. Insulin resistance, skin changes and
virilization: a recessively inherited syndrome possibly due to pineal gland
dysfunction. Diabetologia 1974:10:284-9.
- Kahn
CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes
of insulin resistance and acanthosis nigricans. N EngI J Med 1976:294:739-45
- Gambineri
A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate A et
al. Glucose Intolerance in a Large Cohort of Mediterranean Women With Polycystic
Ovary Syndrome. Phenotype and Associated Factors. Diabetes 2004;53:2353-8
- Flier
JS, Kahn R, Roth J, Bar RS. Antibodies that impair insulin receptor binding
in an unusual diabetic syndrome with severe insulin resistance. Science
1975;
190:63-5
- Flier
JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in
obese women with hyperandrogism, Characterization of an insulin-resistant
state
distinct from the Type A and B syndromes. Diabetes 1985; 34:101-7
- Dunaif
A, HoffmanAR,
Scully RE, Flier JS, Longcope C, Levy LJ.Crowley Jr WF. The clinical,
biochemical and ovarian morphologic features in women with acanthosis nigricans
and masculinization. Obstet Gynecol 1985; 66:545-52
- Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T.
Evidence for distinctive and intrinsic defects in insulin action in polycystic
ovary syndrome. Diabetes 1992; 41:1257-66
- Guzick
D. Polycystic ovary syndrome: symptomatology, path physiology and epidemiology.
Am J Obstet Gyn 1998; 179; S89-93
- Goldzieher
JW, Green JA. The polycystic ovary. Clinical and histologic features. J
clin Endocrinol Metab 1962;22:325-38
- Stein
I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries.
Am J Obstet Gyn 1935;29:181.
- Anderson
KE, Rosner W, Khan MS, New MI, Pang SY, Wissel PS, Kappas A. Diet-Hormone
Interactions: Protein/Carbohydrate Ratio Alters Reciprocally, the Plasma
Levels of Testosterone and Cortisol and their Respective Binding Globulins
in Man.
Life Sciences 1987;40:1 761.
- Hauner,
Ditschnneit RH. Pal SB, Pfeiffer FE. Distribution of adipose tissue and
complications of obesity in overweight women with and without hirsutism.
Dtsch Med Wschr 1987;112:709-13
- Roncari
DAK, Van RLR. Promotion of human adipocyte precursor replication by 17-B-estradiol
in culture. J clin Invest 1977; 62:503-8.
- Moller
DE, Flier JS. Detection of an alteration in insulin receptor gene in a
patient with insulin resistance, acanthosis nigricans and polycystic ovary
syndrome
Engl J Med 1988;319:1526-9.
- Takata
Y, Webster NJG, Olefsky JM. Mutation of the two carboxyl-terminal tyrosines
results in an insulin receptor with normal metabolic signaling but enhanced
mitogenic signaling properties. J Biol Chem 1991; 266:9135-8
- Willis
D, Franks S. Insulin action in human granulosa cells from normal and
polycystic ovaries is mediated by the insulin receptor and not the type-I
insulin-like growth factor receptor. J clin Endocrinol Metab 1995; 80:3788-90.
- Wild
BA, Bartholomew MJ. The influence of body weight on lipoprotein lipids
in patients with polycystic ovary syndrome. Am J Obstet Gynecol. 1988; 159:423-7.
- Dahlgren
E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Polycystic
ovary syndrome and risk for myocardial infarction. Evaluated from a risk
factor model
based on a prospective population study of women. Acta Obstet Gynecol Scand
1992; 71: 599-603.
- Dahlgren
E. Women with polycystic ovary syndrome wedge resected in 1956 to 1965:
a long-term follow up. Fertil Steril. 1992; 57:505-13.
- Mula-Abed
WS, AL-Naemi AH. Prevalence of diabetes in Mosul
city: Comparison of 1997 American Association classification with 1985 World
Health Organization classification. Ann Coll Med Mosul 2002; 28(2): 109-16.
- Legro
RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and Predictors of Risk
for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary
Syndrome, Prospective, Controlled Study in 254 Affected Women. J clin
Endocrinol Metab 1999; 84: 165-9
- Ehrmann
DA, Rosenfield RL, Barnes RB, Karrison T. A longitudinal study of glucose
tolerance in women with polycystic ovary syndrome. Prog 78th 1996, Annual
Meeting of the Endocrine Society.
- Kahn
CR. Insulin action, diabetogenes, and the cause of type 2 diabetes. Diabetes
1994;43:1066-108
- Heather
R. Peppard, Jennifer Marfori, Maria J. Iuorno, and John E. Nestler. Prevalence
of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabetes.
Diabetes Care 2001; 24:1050-2
- Dunaif
A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups
of hyperandrogenic
women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia,
J clin Endocrinol Metab 1987; 65:499-507.
- DeFronzo
RA. The triumvirate: beta-cell, muscle, liver. Collusion responsible for
NIDDM. Diabetes 1988; 37:667-87.
- DeFronzo
RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying
insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
- Bergman
RN, Hope ID, Yang YJ, Watanabe RM, Meador MA, Youn JH, Ader M. Assessment
of insulin sensitivity in vivo: a critical review. Diabetes Metab Rev 1989;
5:411
-29.
- Hollenbeck
C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy
individuals with normal glucose tolerance Clin Endocrinol Metab 1987;
64:1169-73
- Laakso
M. How good a marker is insulin level for insulin resistance? Am J Epidemiol
1993;137:959-65.
- Dunaif
A, Futterweit W. Segal KR, Dobrjansky A. Profound peripheral insulin
resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes
1989; 38: 1165-74
- Yki-Jarvinen
H, Koivisto VA. Effects of body composition on insulin sensitivity. Diabetes
1983;32:965-9
- Caro JF. Dohm LG, Pories WJ, Sinha MK. Cellular alterations in liver,
skeletal muscle, and adipose tissue responsible for insulin resistance
in obesity and Type II diabetes. Diabetes Metab Rev 1989; 5:665-89
- Dunaif
A. Polycystic ovary syndrome and obesity. In: Obesity. J.B. Lippincott
Co., Philadelphia, 1992; pp 594-605
- Kissebah
AH, Peiris AN. Biology of regional body fat distribution: relationship
to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1989; 5:83-109
- Bagatell
CJ, Bremner WJ. Androgens in men-uses and abuses. N
Engl J Med; 1996:334:707-14.
- Ehrmann
DA, Sturis J, Byrne MM, Karrison T, Rosenfleld RL,Polonksy KS. Insulin
secretory defects in polycystic ovary syndrome. Relationship to insulin
sensitivity and family history of non-insulin-dependent diabetes mellitus.
J Clin Invest 1995;96:520-7.
- Knowler
WC, Narayan KMV, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Schersten
B, Pettitt DJ. Preventing non-insulin-dependent diabetes. Diabetes 1995;
44:483-8.
- Keen
H, Rose G, Pyke D, Boyns D, Chlouverakis C, Mistry S. Blood-sugar and
arterial disease. Lancet 1965;2:505-8.
- Anttila
L, Karjala K, Penttila RA, Ruutiainen K, Ekblad U. Polycystic ovaries
in women with gestational diabetes. Obstet Gynecol 1998; 92:13- 6,
© Copyright 2005 - Middle East Fertility Society
|